Skip to content

2025-26 Curation of the BPCA Framework to Enable Pediatric Drug Development

Instructions

In 2022, the Best Pharmaceuticals for Children Act (BPCA) Program developed the BPCA Framework to Enable Pediatric Drug Development, an annotated, selective, curated collection of resources to assist drug developers, researchers, and clinicians with a universal resource of relevant topics for conducting pediatric drug development research.

BPCA Framework to Enable Pediatric Drug Development

The Framework is currently being curated to include additional resources published since the original review in 2021-22. Please use the following pages to assess the selection of resources being considered for inclusion in the 2026 BPCA Framework to Enable Pediatric Drug Development. We anticipate the focus to be on the resources related to your area of expertise, however you are open to review all or to skip those that do not apply. Resources that are highly rated by stakeholders will be added to the Framework through this curation process.

The full Request for Information is available at https://grants.nih.gov/grants/guide/notice-files/NOT-HD-25-004.html

All questions are optional and you may exit this survey at any time. Please contact taylorpe@mail.nih.gov with questions.
OMB # 0925-0766
Expiration Date: 09/2026
Public reporting burden for this collection of information is estimated to average 25 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0766). Do not return the completed form to this address.